EMA Authorised: Vysribli (previously Denosumab Intas) (denosumab) — Intas Third Party Sales 2005 S.L.

View source ↗

Summary

EMA authorised Vysribli (denosumab) for osteoporosis indications, including postmenopausal osteoporosis, with MAH Intas Third Party Sales 2005 S.L.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Vysribli (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Intas Third Party Sales 2005 S.L.. Decision date: 05/01/2026